Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

Molecular Psychiatry

Volumn 4, Issue 5, 1999, Pages 418-428

  Duncan, G E ^a   Zorn, S ^b   Lieberman, J A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Antipsychotic; Clozapine; Dopamine; NMDA; Olanzapine; Quetiapine; Risperidone; Schizophrenia; Ziprasidone

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN ANTAGONIST; ZIPRASIDONE;

AGRANULOCYTOSIS; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0032746356     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000581     Document Type: Review

References (123)

1. 1 Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20-26.
2. 2 Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
3. 3 Bradford DW, Chakos MH, Sheitman BB, Lieberman JA. Atypical antipsychotic drugs in treatment-refractory schizophrenia. Psychiatric Annals 1998; 20: 618.
4. 4 Altar CA, Boyar WC, Wasley A, Gerhardt SC, Liebman JM, Wood PL. Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. Naunyn-Schmiedebergs Arch Pharmacol 1988; 338: 162-168.
5. 5 Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-544.
6. 6 Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G, Wiesel FA. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 1995; 121: 309-316.
7. 7 Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology 1995; 121: 317-322.
8. 8 Fink H, Morgenstern R, Oelssner W. Clozapine - a serotonin antagonist? Pharmacol Biochem Behav 1984; 20: 513-517.
9. 9 Nash JF, Meltzer HY, Gudelsky GA. Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur J Pharmacol 1988; 151: 463-469.
10. 10 Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and Serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-246.
11. 11 Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15: 19S-23S.
12. 12 Flynn SW, MacEwan GW, Altman S, Kopala LC, Fredrikson DH, Smith GN et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 1998; 31: 25-29.
13. 13 Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999; 156: 294-298.
14. 14 Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998; 155: 499-504.
15. 15 Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 1991; 17: 289-309.
16. 16 Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the A typical neuroleptic, clozapine. Br J Psychiatry 1996; 168: 571-579.
17. 17 Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999; 45: 1-16.
18. 18 Curevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 1997; 54: 225-232.
19. 19 Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-614.
20. 20 Seeman P, Corbett R, Van Tol HH. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997; 16: 93-110.
21. 21 Kramer MS, Last B, Getson A, Reines SA. The effects of a selective D4 dopamine receptor antagonist (L-745 870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry 1997; 54: 567-572.
22. 22 Bristow LJ, Kramer MS, Kulagowski J, Patel S, Ragan CI, Seabrook GR. Schizophrenia and L-745 870, a novel dopamine D4 receptor antagonist. Trends Pharm Sci 1997; 18: 186-188.
23. 23 Mansbach RS, Brooks EW, Sanner MA, Zorn SH. Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 1998; 135: 194-200.
24. 24 Faraci WS, Zorn SH, Sanner MA, Fliri A. The discovery of potent and selective dopamine D4 receptor antagonists. Curr Opin Chem Biol 1998; 2: 535-540.
25. 25 Feldpausch DL, Needham LM, Stone MP, Althaus JS, Yamamoto BK, Svensson KA et al. The role of dopamine D4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular adaptations. J Pharmacol Exp Ther 1998; 286: 497-508.
26. 26 Merchant KM, Gill GS, Harris DW, Huff RM, Eaton MJ, Lookingland K, et al. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist. J Pharmacol Exp Ther 1996; 279: 1392-1403.
27. 27 Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96.
28. 28 Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. j Clin Psychiatry 1997; 58 Suppl 10: 28-36.
29. 29 A Beasley CMJ, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997; 58 Suppl 10: 7-12.
30. 30 Tollefson GD, Beasley CMJ, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154: 1248-1254.
31. 31 Tollefson GD, Beasley CMJ, Tran PV, Street JS, Krueger JA. Tamura RN et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-465.
32. 32 Tran PV, Dellva MA, Tollefson GD, Beasley CMJ, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58: 205-211.
33. 33 Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155: 921-928.
34. 34 Tauscher J, Kufferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C et al. In vivo I-123 IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 1999; 141: 175-181.
35. 35 Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998; 155: 914-920.
36. 36 Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286-293.
37. 37 Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998; 3: 123-134.
38. 38 Wadenberg ML. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 1996; 20: 325-339.
39. 39 Costall B, Fortune DH, Naylor RJ, Mardsen CD, Pycock C. Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 1975; 14: 859-868.
40. 40 Waldmeier PC, Delini-Stula AA. Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 1979; 55: 363-373.
41. 41 Kapur S. 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 1996; 124: 35-39.
42. 42 Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-MT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152: 1444-1449.
43. 43 Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS. Comparison of phencyclidine hydrochloride (sernyl) with other drugs: simulation of schizophrenic performance with phencyclidine hydrochloride (sernyl)lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium, II - symbolic and sequential thinking. Arch Gen Psychiatry 1962; 6: 79-85.
44. 44 Luby ED, Cohen BD, Rosenbaum G, Gottilieb JS, Kelley R. Study of a new schizophrenomimetic drug - sernyl. Arch Neurol Psych 1959; 81: 363-369.
45. 45 Bakker CB, Amini FB, Observations on the psychotomimetic effects of sernyl. Compr Psych 1961; 2: 269-280.
46. 46 Davies BM, Beech HR. The effect of 1-arylcyclohexylamine (sernyl) on twelve normal volunteers. J Ment Sci 1960; 106: 912-924.
47. 47 Corssen G, Domino EF. Dissociative anesthesia: further pharmacologic studies and first clinical experience with phencyclidine derivative C1-581. Anesth Analg 1966; 45: 29-40.
48. 48 Domino EF, Chodoff P, Corssen G. Pharmacological effects of CI-581, a new dissociative anesthetic in man. Clin Pharmacol Ther 1965; 6: 279-291.
49. 49 Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308.
50. 50 Olney JW, Farber NB. Clutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
51. 51 Deutsch SI, Mastropaolo J, Schwartx BL, Rosse R, Morihisa JM. A 'glutamatergic hypothesis' of schizophrenia. Clin Neuropharmacol 1989; 12: 1-13.
52. 52 Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996; 3: 241-253.
53. 53 Yenari MA, Bell TE, Kotake AN, Powell M, Steinberg GK. Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients. Clin Neuropharmacol 1998; 21: 28-34.
54. 54 Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
55. 55 Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al. NMDA receptor function and human cognition -the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14: 301-307.
56. 56 Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory, and sermantic memory in healthy volunteers. Biol Psychiatry 1998; 43: 811-816.
57. 57 Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6: 869-872.
58. 58 Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-10.
59. 59 Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-150.
60. 60 Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis - preliminary observations. Biol Psychiatry 1970; 2: 95-107.
61. 61 Griffith J, Cavanaugh J, Held N, Oates J. D-Amphetamine evaluation of psychotomimetic properties in man. Arch Gen Psychiatry 1972; 26: 97-100.
62. 62 Lieberman JA, Kane JM, Alvir JAJ. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987; 91: 415-433.
63. 63 Ferrer-Allado T, Brechner VL, Dymond A, Cozen H, Crandall P. Ketamine induced electroconvulsive phenomena in human limbic and thalamic regions. Anesthesiology 1973; 38: 333-344.
64. 64 Winters WD, Ferrer-Allado T, Guzman-Flores C, Alcaraz M. The cataleptic state induced by ketamine - a review of the neuropharmacology of anesthesia. Neuropharmacology 1972; 11: 303-315.
65. 65 Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate. Br J Pharmacol 1983; 79: 565-575.
66. 66 Thomson AM, West DC, Lodge D. An N-methyl-aspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature 1985; 313: 479-481.
67. 67 White PF, Way WL, Trevor AJ. Ketamine - its pharmacology and therapeutic uses. Anesthesiology 1982; 56: 119-136.
68. 68 Sinclair JG, Tien AF. Neuronal responses to ketamine administered microiontophoretically or intraperitoneally in the rat. Gen Pharmacol 1979; 10: 51-55.
69. 69 Nelson SR, Howard RB, Cross RS, Samson F. Ketamine-induced changes in regional glucose utilization in the rat brain. Anesthesiology 1980; 52; 330-334.
70. 70 Hammer RP, Herkenham M. Altered metabolic activity in the cerebral cortex of rats exposed to ketamine. J Comp Neurol 1983; 220: 396-404.
71. 71 Duncan GE, Leipzig JN, Mailman RB, Lieberman JA. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 1998; 812: 65-75.
72. 72 Duncan GE, Moy SS, Knapp DJ, Mueller RA, Breese GR. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 1998; 787; 181-190.
73. 73 Kurumaji A, Nehls DG, Park CK, McCulloch J. Effects of NMDA antagonists, MK-801 and CPP, upon local cerebral glucose use. Brain Res 1989; 496: 268-284.
74. 74 Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA. Comparison of brain metabolic activity patterns induced by ketamine, MK801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic doses of ketamine. Brain Res (in press).
75. 75 Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154: 805-811.
76. 760 Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)-and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 1997; 7: 25-38.
77. 18F]fluorodeoxyglucose (FDC). Eur Neuropsychopharmacol 1997; 7: 9-24.
78. 78 Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996; 16: 2034-2043.
79. 79 Coppel DL, Bovill JG, Dundee JW. The taming of ketamine. Anesthesia 1973; 28: 293-296.
80. 80 Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998; 135: 213-229.
81. 81 Liu J, Moghaddam B. Regulation of glutamate efflux by excitatory amino acid receptors evidence for tonic inhibitory and phasic excitatory regulation. J Pharmacol Exp Ther 1995; 274: 1209-1215.
82. 82 Moghaddam B, Adams B, Verman A, Daly D. Activation of glutamatergic neurotransmission by ketamine - a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-2927.
83. 83 Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotrophic glutamate receptor agonist in rats. Science 1998; 281: 1349-1352.
84. 84 Hauber W, Andersen R. The non-NMA glutamate receptor antagonist GYKI Y1-52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn Sch Arch Pharmacol 1993; 348: 486-490.
85. 85 Rubser M, Tzschentke T, Hauber VV. Behavioural and neurochemical interactions of the AMPA antagonist GYKI Y1-52460 and the non-competitive NMDA antagonist dizocilpine in rats. J Neural Trans 1995; 101; 115-126.
86. 86 Willins DL, Narayanan S, Wallace LJ, Uretsky NJ. The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharmacol Biochem Behav 1993; 46: 881-887.
87. 87 Fix AS, Horn JW, Wightman KA, Johnson CA, Long GG, Storts RW et al. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol 1993; 123: 204-215.
88. 88 Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity - mechanism and protection. Science 1991; 154: 1515-1518.
89. 89 Horvath ZC, Czopf J, and Buzsaki G. MK-801-induced neuronal damage in rats. Brain Res 1997; 753: 181-195.
90. 90 Farber NB, Price MT, Labruyere J, Nemnich J, St Peter H, Wozniak DF et al. Antipsychotic drugs block phoncyclidine receptor-mediated neurotoxicity. Biol Psychiatry 1993; 34: 119-121.
91. 91 Farber NB, Foster J, Duhan NL, Olney JW. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr Res 1996; 21: 33-37.
92. 92 Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 1995; 120: 67-74.
93. 93 Tiedtke PI, Bischoff C, Schmidt WJ. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. [Neural Trans 1990; 81: 173-182.
94. 34 Hoffman DC. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Trans 1992; 89: 1-10.
95. 95 Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 1995; 122: 198-201.
96. 96 Bukshi VP, Swerdlow NR, Geyer MA. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 1994; 271: 787-794.
97. 97 Swerdlow NR, Bakshi VP, Geyer MA. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 1996; 279: 1290-1299.
98. 98 Swerdlow NR, Keith VA, Braff DL, Geyer MA. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther 1991; 256: 530-536.
99. 99 Keith VA, Mansbach RS, Geyer MA. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 1991; 30: 557-566.
100. 100 Duncan GE, Leipzig JN, Miyamoto S, Mailman RB, Lieberman JA. Regional brain metabolic activity is affected differentially by typical and atypical antipsychotic drugs in rats, Schizophr Res 1999; 36: 307.
101. 101 Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D-1, D-2, D-3, 5HT(2A) and muscarinic receptors. Psychopharmacology 1999; 141: 267-278.
102. 102 Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. Clozapine and haloperidol modulate N-methyl-D-aspartate-and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 1997; 283: 226-234.
103. 103 Wang RY, Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 1998; 19: 74-85.
104. 104 Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. Neuroreport 1995; 6: 2500-2504.
105. 105 Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 1997; 42: 664-668.
106. 106 Leeson PD, Iversen LL. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J Med Chem 1994; 37: 4053-4067.
107. 107 Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG et al. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 1989; 12: 416-424.
108. 108 Costa J, Khaled E, Sramek J, Bunney WJ, Potkin SG. An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J Clin Psychopharmacol 1990; 10: 71-72.
109. 109 Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169: 610-617.
110. 110 Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP, Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994; 151: 1234-1236.
111. 111 Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56: 29-36.
112. 112 van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996; 40: 1298-1300.
113. 113 Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21-27.
114. 114 Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995; 152: 1213-1215.
115. 115 Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-Cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153: 1628-1630.
116. 116 Coff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45: 512-514.
117. 117 Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999; 156: 145-147.
118. 118 Mashimoto A, Oka T, Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol 1997; 52: 325-353.
119. 119 Tsai G, Pinchen Y, Chung L-C, Lange N. Coyle JT. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081-1089.
120. 120 Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 1998; 59; 585-588.
121. 121 Farber NB, Newcomer JW, Olney JW. Glycine agonists - What can they teach us about schizophrenia? Arch Gen Psychiatry 1999; 56: 13-17.
122. 122 Goff DC, Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophr Res 1997; 27: 157-168.
123. 123 Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 1998; 95: 15730-15734.